A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature

Trial Profile

A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Short stature
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 04 Apr 2017 Primary endpoint (Change From Baseline in Height Velocity at Month 6 Using Last Observation Carried Forward (LOCF) Method) has been met, according to results presented at The 99th Annual Meeting of the Endocrine Society.
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society.
    • 20 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top